Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05399836
Other study ID # 803194 SSS PSE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 30, 2022
Est. completion date October 12, 2022

Study information

Verified date January 2023
Source University of Liverpool
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Reducing food portion size is a potential strategy to reduce energy intake. However, it remains unclear who is most susceptible to the portion size effect (PSE). There are just two studies which have examined the PSE in the context of socioeconomic position (SEP), with mixed findings. In an online trial the PSE on intended consumption of unhealthy snacks was 18-24% larger for participants of lower SEP compared to participants of higher SEP. However, in a recent laboratory study which examined the PSE on total daily energy intake, participants of lower SEP were no more susceptible to the influence of portion size on eating behaviour than participants of higher SEP. Further research is required to elucidate these divergent findings. There is also an absence of evidence examining the moderating role of subjective social status (SSS) - an individual's perceived standing in society - on the PSE. Given evidence that the subjective experience of social class may be associated with health outcomes, the present study examines whether reductions to the portion size reduces daily energy intake, and whether and how SSS (higher vs lower) moderates the PSE. In a crossover experiment, participants will be served all meals in the lab on two separate days, with the portion size of main components at breakfast, lunch and dinner manipulated (i.e. smaller on one day vs larger on the other day). All other foods offered are identical. Food intake from the portion-manipulated breakfast, lunch and dinner, as well as all other meal components (non-portion-manipulated sides, dessert, seconds, snacks, etc.) will be measured, to assess total daily energy intake (kcal).


Description:

See Study Protocol attached.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date October 12, 2022
Est. primary completion date October 12, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female - UK (United Kingdom) residents, able to visit laboratory in Liverpool - Aged 18 or over - Fluent in English - willing to consume the test foods - Self report willingness to eat test foods - BMI between 18.5 - 32.5kg2 Exclusion Criteria: - participation in our previous study - food allergies, intolerances or specific dietary requirements (except vegetarian) - taking medication which affects appetite - currently pregnant - history of eating disorders - currently on a diet to lose weight

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Portion size manipulation
The intervention will be administered via changing portion sizes of foods served to participants.

Locations

Country Name City State
United Kingdom University of Liverpool Liverpool

Sponsors (2)

Lead Sponsor Collaborator
University of Liverpool European Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Daily energy intake Total energy (kcal) consumed from breakfast, lunch, dinner, dessert, snackbox, and any self-reported additional foods. Time Frame: 24 hours after intervention administered
Secondary Energy intake from portion-manipulated foods Total energy (kcal) consumed from portion-manipulated foods at breakfast, lunch, and dinner Time Frame: 24 hours after intervention administered
Secondary Energy intake from non portion-manipulated foods Total energy (kcal) consumed from other foods (no portion-manipulation) at breakfast, lunch, dinner, snacks, and self-reported foods. Time Frame: 24 hours after intervention administered
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2